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Background: Predicting outcome of breast cancer (BC) patients based on sentinel lymph node (SLN) status without ax-
illary lymph node dissection (ALND) is an area of uncertainty. It inﬂuences the decision-making for regional nodal irradi-
ation (RNI). The aim of the NORA (NOdal RAdiotherapy) survey was to examine the patterns of RNI.
Methods: A web-questionnaire, including several clinical scenarios, was distributed to 88 EORTC-afﬁliated centers.
Responses were received between July 2013 and January 2014.
Results: A total of 84 responses were analyzed. While three-dimensional (3D) radiotherapy (RT) planning is carried out in
81 (96%) centers, nodal areas are delineated in only 51 (61%) centers. Only 14 (17%) centers routinely link internal
mammary chain (IMC) and supraclavicular node (SCN) RT indications. In patients undergoing total mastectomy (TM) with
ALND, SCN-RT is recommend by 5 (6%), 53 (63%) and 51 (61%) centers for patients with pN0(i+), pN(mi) and pN1, re-
spectively. Extra-capsular extension (ECE) is the main factor inﬂuencing decision-making RNI after breast conserving
surgery (BCS) and TM. After primary systemic therapy (PST), 49 (58%) centers take into account nodal ﬁbrotic changes in
ypN0 patients for RNI indications. In ypN0 patients with inner/central tumors, 23 (27%) centers indicate SCN-RT and
IMC-RT. In ypN1 patients, SCN-RT is delivered by less than half of the centers in patients with ypN(i+) and ypN(mi).
Twenty-one (25%) of the centers recommend ALN-RT in patients with ypN(mi) or 1–2N+ after ALND. Seventy-ﬁve (90%)
centers state that age is not considered a limiting factor for RNI.
Conclusion: The NORA survey is unique in evaluating the impact of SLNB/ALND status on adjuvant RNI decision-
making and volumes after BCS/TM with or without PST. ALN-RT is often indicated in pN1 patients, particularly in the
case of ECE. Besides the ongoing NSABP-B51/RTOG and ALLIANCE trials, NORA could help to design future speciﬁc
RNI trials in the SLNB era without ALND in patients receiving or not PST.
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introduction
Predicting breast cancer (BC) outcome based on sentinel lymph
node (SLN) status without axillary lymph node dissection (ALND)
is a new area of uncertainty for regional nodal irradiation (RNI) in
the adjuvant setting or after primary systemic therapy (PST).
The updated clinical practice guidelines report from the
American Society of Clinical Oncology [1] concluded that for
patients with early-stage BC with negative SLN and those with
1–2 metastatic SLN receiving whole breast irradiation (WBI)
should not undergo ALND. Conversely, women with SLN me-
tastases who will undergo total mastectomy (TM) should be
offered ALND. These recommendations are mainly based on
two randomized trials [2, 3]. However, several concerns remain
about these trials including the short follow-up and the uncer-
tain coverage of the axilla by the tangential ﬁelds (TgF) used
with three-dimensional conformal radiotherapy (3D-CRT) [4].
In addition, (i) the risk of non-SLN involvement in the axilla
depends on the size of SLN metastasis, (ii) locoregional disease
control is important for survival and quality of life, (iii) RNI
increases disease-free and overall survival [5–7] and (iv) axillary
lymph node radiotherapy (ALN-RT) can allow equivalent re-
gional control to ALND in SLN-positive patients [8].
Having appreciated the importance of RNI in the era of
modern radiotherapy and axillary surgery, some national groups
have published guidelines with particular attention to RNI [9,
10]. However, these guidelines are not widely implemented na-
tionally and decision-making still depends mainly on local policy.
The NORA (NOdal RAdiotherapy) survey was designed to
examine the patterns of RNI practice in European Organization
for Research and Treatment of Cancer (EORTC) afﬁliated
centers according to different clinical scenarios observed after
SLNB followed or not by ALND in patients undergoing breast-
conserving surgery (BCS) or TM with or without PST. The
results may help to provide a basis for designing future trials in
areas of equipoise in clinical decision-making concerning RNI.
methods
NORA survey was designed to examine the contemporary practice of RNI in
EORTC centers. The web-questionnaire was distributed to 88 EORTC
centers. Responses from representative of the afﬁliated centers were regis-
tered between July 2013 and January 2014.
The questionnaire included four sections. The ﬁrst section was dedicated
to the BC-related workload, local radiotherapy indications and planning pro-
tocols. The rest of the questionnaire has focused on RNI indications after
BCS or TM with or without PST. In each of the scenarios, questions were
addressed regarding SLNB either followed or not by ALND, and included all
nodal involvement status, from tumor cells to ≥10N+. For each situation, in-
ternal mammary chain (IMC-RT), supra/infraclavicular (SCN-RT) and
ALN-RT indications were questioned.
results
institutions and local policy for radiotherapy
practice
The distribution of centers, the number of patients treated per
month, the use of multidisciplinary meetings and radiotherapy
technique validation are presented in Table 1.
RNI after BCS
When IMC-RT is indicated (for N-, central/inner tumors, for
example), only 14 (17%) centers reported to systematically indi-
cate additional SCN-RT. Only half of the centers advocated
SCN-RT for intermediate risk patients (1–3N+). For macrome-
tastatic SLN involvement in patients without ALND, 13 (5%),
55 (65%) and 48 (57%) centers recommended RNI involving
IMC, SCN and ALN, respectively (Table 2).
Regarding the radiotherapy technique used for axillary cover-
age, 21 (25%) centers responded that TgF are sufﬁcient to cover
residual axillary disease in patients with positive SLNs without
ALND.
RNI post-mastectomy
In post-mastectomy radiotherapy (PMRT), adverse standard
pathological prognostic factors did not impact volume deﬁnition
for RNI. SCN-RT was recommended as a standard of care for
patients with pN0(i+), pN(mi) and pN1 disease in 5 (6%), 53
(63%) and 51 (61%), respectively. Extra-capsular extension
(ECE) is considered as the main factor for ALN-RT indication.
Furthermore, 34 (40%) centers prescribe ALN-RT in patients
with ≥3–4 positive LNs after ALND, irrespective of the number
of examined axillary LNs (Table 2).
RNI after PST
Out of 84 centers, 68 (81%) use pre-PST imaging±biopsy for
staging and 63 (75%) declared that the pre-PST nodal status dic-
tates volumes deﬁnition for RNI.
Table 1. Practice in the centers and radiotherapy technique
n %
Centers
Comprehensive cancer centers 45 54
University hospitals 18 21
Public community hospitals 16 19
Private facilities 5 6
No. of BC patients per month
>25 34 40
25–50 29 35
>50 21 25
Validation of RT multidisciplinary meeting
Yes 80 95
No 4 5
Validation of RT in a technical board meeting
Yes 69 82
No 15 18
3D-CRT planning to all patients
Yes 81 96
No 3 4
Nodal systematic delineation
Yes 51 61
No 33 39
3D-CRT, three-dimensional conformal radiotherapy; BC, breast
cancer.
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In patients with ypN0, 67 (80%) centers do not routinely pre-
scribe RNI. Nodal volume deﬁnition take into account the ﬁnal
pathological ﬁbrotic changes observed in the axillary LNs in 49
(58%) centers. In ypN0 patients with inner and centrally located
tumors, 32 (39%) centers treat the SCN area either alone or in-
cluding IMC in 23 (27%) centers (Table 3).
Nodal irradiation in elderly patients
Out of 84 centers, 82 (98%) reported that RNI is not particularly
omitted in patients >70 years of age. Seventy-ﬁve centers (90%)
responded that they had no ﬁxed upper age limit for RNI.
discussion
The term, RNI, is not uniformly deﬁned in the literature. In his-
toric series, RNI was used to describe large nodal irradiation.
After surgery including ALND, ALN-RT and IMC-RT indica-
tions have declined over time, because of the low beneﬁt/risk
ratio for arm lymphedema and increased risk of vascular and
cardiac morbidity/mortality. On the other hand, it is widely
recognized that advances in radiotherapy techniques, and sys-
tematic multidisciplinary validation of indications have contrib-
uted to a marked decrease in late toxicity [11]. In the NORA
survey, 80 (95%) centers stated that radiotherapy indications are
conﬁrmed at a multidisciplinary meeting and 69 (82%)
routinely validate volumes and technique in a dedicated
meeting. However, nodal areas are delineated in only 51 (61%)
centers. LNs area delineation is particularly important for evalu-
ation of nodal coverage when the complete axillary status is
unknown [4]. Before the advent of 3D-CRT, the evaluation of
the dose distribution of RNI was impossible. These considera-
tions also apply for recent studies that provide new evidence of
the survival beneﬁt of RNI [5–7].
RNI by site
In contrast to PMRT [12], the beneﬁt from separate irradiation
of the different nodal areas has never been investigated in a ran-
domized trial after BCS. Thus, it is difﬁcult to quantify the con-
tribution to improved outcome achieved by radiotherapy of the
distinct sites. Table 4 summarizes an overview of RNI published
data, guidelines and NORA survey results.
supraclavicular node radiotherapy
RNI indications and volumes are generally based on clinico-
pathological factors [10]. Yu et al. [13] reported a close relationship
between 5-year SCN failure and reduced overall survival in 448
pN1 patients without radiotherapy. Also, ECE was one of the main
independent risk factors. When considering only patients with
1–3N+, SCN recurrence has a deleterious impact on outcome with
Table 2. Nodal radiotherapy after breast conservative surgery or total mastectomy
Radiotherapy after breast conservative surgery
Systematic SCN-RT if IMC is indicated n %
Yes 14 17
No 70 83
Nodal RT volumes according to SLN status (with ALND)
Nodal status IMC-RT (n) SCN-RT (n) ALN-RT (n)
pNi+ 0 3 (4%) 3 (4%)
pNmicro 2 (2%) 20 (24%) 6 (7%)
pNmacro 11 (13%) 55 (65%) 2 (2%)
Nodal RT volumes according to SLN status (without ALND)
pNi+ 1 (1.2%) 7 (8%) 12 (14%)
pNmicro 4 (5%) 29 (34%) 29 (34%)
pNmacro 13 (15%) 55 (65%) 48 (57%)
Tangential fields involve axilla for potential residual disease
n %
Yes 21 25
No 63 75
Radiotherapy after total mastectomy
pNi+ pNmi pN1
SCN-RT indications 5 (6%) 53 (63%) 51 (60%)
SCN-RT — 9 (11%) —
ECE (−) — — 16 (19%)
ECE (+) — — 25 (30%)
ALN-RT — —
3–4N+ — — 34 (40%)
SLN, sentinel lymph node (biopsy); ALND, axillary lymph node dissection; RT, radiotherapy; SCN-RT, supraclavicular radiotherapy; IMC-RT, internal
mammary chain radiotherapy; ALN-RT, axillary lymph node radiotherapy; pN: pathologic nodal status.
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only 18% of survival at 10 years [14]. In the NORA survey, 55
(65%) centers indicate at SCN-RT in the case of nodal macrometa-
static disease irrespective of SLN or ALND. This rate was lower
(34%) in the case of micrometastatic SLN involvement without
ALND (Table 2). In Canada, the use of SCN-RT in patients with
1–3N+ increased from 23% prior 1997 to 57% thereafter [15]. This
was probably due to: (i) the publication of the late results of the
PMRT trial that showed a beneﬁt of PMRT including comprehen-
sive RNI for pN1 patients [16] and (ii) the improved 10-year loco-
regional control by RNI in a large retrospective analysis of 2768
pN1 from the British Columbia database [15].
In terms of recommendations, while the early German (S3
and AGO) [17] guidelines were more restrictive with regard to
SCN-RT indications, others such as the French [10], the US-
NCCN and the recent German Society of Radiation Oncology
(DEGRO) guidelines do recommend systematic SCN-RT for
patients with 1–3N+ [1, 8, 10]. However, these guidelines cannot
distinguish the contribution of SCN-RT from the potential
effect of IMC-RT on outcome. They are mainly based on the
balance between high risk of SCN recurrence and the fear tox-
icity of IMC-RT. This beneﬁt/risk ratio has advocated the wide
use of SCN-RT without IMC-RT in North America [18]. The
NORA survey showed that a very low rate of centers (17%) sys-
tematically link SCN-RT indication to IMC-RT.
internal mammary chain radiotherapy
It is important to distinguish BCS and PMRT studies for IMC-
RT indications. IMC-RT was part of the treatment in most
PMRT studies [16, 19] and the two major randomized trials in-
vestigating RNI [5, 6]. Only the French randomized trial has
speciﬁcally addressed the question of IMC-RT contribution as
part of PMRT [12]. This trial included 1334 patients who had
chest wall and SCN-RT and were randomized to receive or not
IMC-RT. The authors conceded that the study might have been
underpowered to prove any signiﬁcant survival beneﬁt for IMC-
RT. They admitted that their data do not permit a deﬁnite con-
clusion [12]. These results are in contrast to the large French
cohort study on 1630 patients, which showed a signiﬁcant sur-
vival beneﬁt at 10 (+12%) and 20 years (+24%) of IMC-RT in
patients with medial/central tumors [20].
In the European EORTC 22922-10925 study, the question of
IMC-RT was addressed in 4004 patients among whom 23% had
PMRT. They concluded that IMC-RT should be recommended
for patients with involved axillary LNs and/or medially located
tumors. Further, in the MA20 trial, RNI, deﬁned as target volume
including axilla levels I-III, SCN and IMC nodes, increased locor-
egional control and survival without distant metastases [6].
In terms of guidelines, the NCCN [1] states that IMC-RT
should be ‘strongly considered’ for pN1 patients, regardless of the
number of affected nodes and irrespective of type of surgery and
even for pN0 patients with tumors ≥5 cm after TM. The French
guideline recommends, ‘SCN and IMC nodes should be system-
atically irradiated in patients with internal-central tumors and
pN1’ [10]. The NORA survey showed that centers consider IMC-
RT indications differently from the other nodal areas in the case
of macrometastatic SLN involvement without ALND. Only 13
(15%) centers recommend IMC-RT, while 55 (65%) and 48
(57%) centers indicated SCN-RT and ALN-RT, respectively. It
should be noted that the survey was conducted before the results
of the analysis of the EORTC 22922-10925 trial were known [5].
axillary lymph node radiotherapy
The other controversy concerns axillary irradiation indications
in the SLNB era [21]. It has been shown in randomized trials
that SCN-RT plus ALN-RT, which are systematically linked as
one RT volume, is as effective and less toxic than ALND alone
[8]. Thus, with the widespread introduction of the SLNB pro-
cedure for staging and the consequently decreased use of
ALND, the latter procedure may be increasingly replaced by
ALN-RT.
In the NORA survey, 48 (57%) and 55 (65%) of centers indicate,
respectively, SCN-RT and ALN-RT in cases of macrometastatic
SLN involvement without ALND. In patients with ≥3–4N+, 40%
of the centers prescribe ALN-RT irrespective of the number of
examined axillary LNs with a signiﬁcant impact of ECE status
on volume deﬁnition.
In the French consensus statement, only patients ‘with massive
involvement after ALND and those who have no ALND’ should
undergo axillary radiotherapy [10]. Recently, the DEGRO panel
stated, ‘data do not permit ultimate conclusions whether any
local treatment of the axilla can be safely omitted in selected
patients with 1–2 involved LNs or in case of micrometastases’.
In cases of macroscopic SLN metastases, they concluded that
Table 3. Nodal radiotherapy after primary systemic therapy
and surgery
Decision for nodal RT according to pretreatment nodal status
n %
Yes 63 75
No 21 25
Decision for nodal RT according to post-operative fibrotic scars in
pN0 patients
Yes 49 58
No 35 25
Decision for nodal RT in pN0 patients with an unknown pre-PST
nodal status
Yes 59 70
No 25 30
Decision for nodal RT in proven pN0 pre-PST nodal status
Yes 17 20
No 67 80
Decision for nodal RT in after PST
Volumes SCN-RT (n) IMC-RT (n) ALN-RT (n)
ypN0 BUT inner or
central tumors
23 (27%) 32 (38%) —
ypN0i+ 22 (26%) 6 (7%) —
ypNmi 30 (36%) 8 (10%) —
ypN+ (1N+) 44 (52%) 12 (14%) 21 (25%)
ypN+ (2N+) 58 (69%) 15 (18%)
ypN+ (> 3N+) 67 (80%) 26 (31%) 34 (40%)
ALND, axillary lymph node dissection; RT, radiotherapy; SCN-RT,
supraclavicular radiotherapy; IMC-RT, internal mammary chain
radiotherapy; ALN-RT, axillary lymph node radiotherapy; pN,
pathologic nodal status.
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ALN-RT (as part of RNI) should be discussed as an alternative
to ALND [9]. The German recommendations are mainly based
on the AMAROS trial results showing that ALN-RT and ALND
provided both excellent and comparable locoregional control
and survival at 5 years with, however, signiﬁcantly increased in-
cidence of arm lymphedema in the latter [8]. However, the
design and the results of the AMAROS may raise discussion
regarding: (i) the potential ‘overtreatment’ using extensive RNI
including axilla levels, (ii) the imbalance in the distribution of
SNL-positive patients in the two arms, (iii) the 5-year axillary
recurrence rate which was far below that hypothesized and (iv)
the short follow-up which could not result in enough axillary
recurrences for sufﬁcient statistical power and better evaluation
of late cardiac toxicity.
When ALN-RT is indicated, the debate concerns the tech-
nique and dose optimization. The excellent outcome observed
in the ACOSOG-Z0011 trial was attributed to the coincident
dose to the axilla delivered by the TgF used to treat the breast
volume [2]. Radiotherapy nodal volumes details were available
from the report forms of only 605 patients. The radiotherapy
charts could be reviewed in only 288 patients. No clear conclu-
sion could be drawn from the analysis on whether additional
RNI was necessary or beneﬁcial for these patients [22].
A compromise accounting for a potentially increased risk of
locoregional recurrence of SLN-positive patients was proposed
by Henri Mondor team. Their approach to use ‘high TgF’ or
‘direct ﬁelds’ to cure potential axillary residual disease was sup-
ported by the limited coverage of axillary contents including the
SLNB area when only standard TgF are planned to treat the
axilla [4, 21]. In the NORA survey, only 21 (25%) centers
declared that TgF cover residual axillary disease adequately in
SLN-positive patients without ALND.
RNI by site after PST and surgery
PST is the accepted approach for women with locally advanced
BC for whom immediate surgery is not feasible. Usually, an
ultrasound-guided ﬁne needle aspiration of suspicious nodes is
carried out before PST to determine axillary nodal status. The
NORA survey showed that 68 (81%) centers use pre-PST
imaging and/or biopsy for staging.
The indications for adjuvant radiotherapy in patients who
underwent PST are generally based on similar prognostic factors
as those used to indicate radiotherapy following primary BCS or
TM [10]. Therefore, the pre-PST disease criteria are important
as they often dictate the RNI volumes. In NORA survey, 63
Table 4. Regional nodal irradiation by site published in the literature and guidelines
SCN-RT±IMC-RT indication
Criteria Retrospective literature Randomized trials National guidelines
[1, 10, 11, 21]
NORA survey
pN0 No SCN-RT needed for pN0 MA20: benefit for only
high-risk patients [7]
EORTC: inner/central
tumors [6]
Not recommended Indications in inner/central
tumors: 23% (SCN-RT) and
32% (IMC-RT) of centers
Macrometastasis RNI did not affect the rate of axillary
failure or supraclavicular failure in
patients with 1–3 N+ [17]
Benefit for RNI [7] Similar to 1−N+ but not
particularly specified
SCN-RT in 55 (65%) centers
IMC-RT in 11 (13%) centers
1–3 N+ Loco-regional±survival benefit
[18, 20, 24]
IMC-RT: survival benefit [24]
PMRT: OS benefit
[20, 23]
Data from EORTC and
MA20 for RNI [6, 7]
Increase indication of
SCN-RT in Canada
(57%) [19]
Restrictive in early
German S3 guidelines
[10]
Systematic SCN-RT:
French [11]
DEGRO [10]
NCCN [1]
Indication declared by 50% of
the centers
ECE: main factor for decision-
making
>4 N+ Loco-regional±survival benefit
[18, 20, 24]
IMC-RT: survival benefit [24]
RNI irradiation indicated Indicated by 40% of the centers
ALN-RT Indications
Guidelines NORA survey
NCCN [1] French [11] DEGRO [10, 21]
Criteria BCS and SLNB: 1 or 2 positive SLN:
no ALD if WBI (tangential fields)
Positive SLN and no
ALND
Massive involvement of
LNs in ALND
SLNB without ALND
Indication for:
1–2 LNs +
Micrometastasis
Macrometastases
SLNB without ALND:
pNmi: 29 (34%) centers
pNmacro: 48 (57%)
SLNB and ALND:
pNi+ to pNmacro: <7%
ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; RT, radiotherapy; RNI, regional nodal irradiation; SCN-RT, supraclavicular
radiotherapy; IMC-RT, internal mammary chain radiotherapy; ALN-RT, axillary lymph node radiotherapy; pN, pathologic nodal status.
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(75%) centers declared that the pre-PST nodal status dictated
their decision for RNI. In ypN0 patients, 67 (80%) centers do
not advocate RNI, while 49 (58%) centers reported taking into
account the pathological ﬁbrotic changes observed in the axil-
lary LNs of ypN0 patients with an unknown nodal status before
PST. The ongoing NSABP-B51/RTOG trial was designed to test
RNI in patients with positive ALNs before PST who converted
to ypN0 either after TM or BCS [23].
In cases of ypN1, there were predictably a higher number of
centers that indicate RNI by site according to the degree of in-
volvement. SCN-RT is delivered by 36–80% of the centers in
patients with ypN(i+) to >3–4N+ disease. Axillary volume alone
is irradiated in 25% and 40% of the centers in patients with ypN
(mi) or 1–2N+ and >3–4N+ disease, respectively. These differ-
ences between centers probably reﬂect uncertainties among ra-
diation oncologists on the indications for RNI and appropriate
volumes in the adjuvant setting. The ongoing phase III ALLIANCE
trial has been designed in patients with cT1-3N1 BC to compare
ALND with axillary irradiation in patients with residual 1–6
SLN/non-SLN-positive after PST [23].
RNI in elderly patients
While Oxford overview of BCS trials showed a twofold reduc-
tion in ﬁrst relapse even in ‘low risk’ older patients, the recent
report from the SIOG-task force could not draw any RNI guide-
lines for BC elderly patients [24]. Indeed, RNI has never been
considered as a relevant question for elderly patients. Converse-
ly, when considering breast radiotherapy, the CALGB9343 trial
showed in patients aged ≥70 year with tumors ≤2 cm, a super-
iority of combined WBI+tamoxifen over tamoxifen alone in
terms of local control. However, this gain did not translate into
an advantage for 10-year survival [25]. In NORA survey, adju-
vant RNI indication is neither restricted by an upper age limit
(90% of the centers) nor omitted in patients over 70 years (98%
of the centers).
conclusion
NORA is the ﬁrst survey that aimed to evaluate the practice of
RNI by site in the contemporary context of SLNB and 3D-CRT.
ALN-RT is indicated by 40% of the centers in patients with ≥3–4
positive LNs, irrespective of the number of nodes examined in the
ALND. New trials testing RNI in the SLN micro/macrometastases
patients are needed.
In the PST setting, the large majority of the centers do not indi-
cate RNI in ypN0 patients. While ALLIANCE trial aims to deter-
mine the best nodal management option (ALND versus RNI) in
post-PST SLN/non-SLN-positive patients, and NSABP-B51/
RTOG investigate the need of RNI in complete responders, ques-
tions on RNI indications by sites and by BC molecular subtypes
are pending. Additionally, a trial investigating RNI in ypN0
patients with pre-PST cN0 or Nx status could help to determine
the role of radiotherapy in locoregional control and its impact on
survival.
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Role of circulating tumor cells as prognostic marker
in resected stage III colorectal cancer
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Background: The prognostic role of circulating tumor cells (CTC) in early colorectal cancer (CRC) has not been deter-
mined yet. We evaluated the potential prognostic value of CTC in stage III CRC patients.
Patients and methods: Prospective multicenter study of 519 patients with stage III CRC recruited between January
2009 and June 2010. CTC were enumerated with the CellSearch System after primary tumor resection and before the
start of adjuvant therapy. A total of 472 patients were included in the analysis.
Results: CTC ≥1, ≥2, ≥3 and ≥5 were detected in 166 (35%), 93 (20%), 57 (12%) and 34 (7%) patients, respectively.
Median follow-up was 40 months. In the overall population, CTC ≥1 (disease-free survival (DFS): HR 0.97, P = 0.85;
overall survival (OS): HR 1.03, P = 0.89), ≥2 (DFS: HR 1.07, P = 0.76; OS: HR 1.02, P = 0.95), ≥3 (DFS: HR 0.96,
P = 0.87; OS: HR 0.74, P = 0.41) and ≥5 (DFS: HR 0.72, P = 0.39; OS: HR 0.48, P = 0.21) were not associated with
worse DFS and OS. No clinicopathological characteristics were signiﬁcantly associated with the presence of CTC. In
patients with disease relapse, the proportion with CTC ≥1 was not signiﬁcantly different between those with single versus
multiple metastatic locations (37.9% versus 31.4%, P = 0.761). In the multivariate analysis, CTC ≥1 was not an independ-
ent prognostic factor for DFS (HR 0.97, P = 0.87) and OS (HR 0.96, P = 0.89).
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